52 results about "Antidepressant medication" patented technology

The invention belongs to the technical field of biomedicine, and particularly relates to a benzenesulfonamide derivative and application of the benzenesulfonamide derivative in antidepressant drugs. The structural general formula of the compounds is (I), the compounds or pharmaceutically acceptable salts thereof have agonistic activity on 5-hydroxytryptamine 2A type receptors, and the compounds are determined to have good anti-depression activity through a mouse tail suspension experimental model, an open field experimental model and a forced swimming experimental model. The compound is an anti-depression compound which is novel in structure and wide in application prospect, has no magical effect, and can be developed into an anti-depression treatment medicine.

The invention belongs to the technical field of biomedicine, and particularly relates to application of carboline compounds in preparation of antidepressant drugs. According to the present invention, the carboline compound or the pharmaceutically acceptable salt thereof can target the 5-HT2A receptor, and has the 5-HT2A receptor excitation activity; the compound can effectively relieve depression symptoms of mice in a mouse spontaneous activity experiment model, a tail suspension experiment model and an open field experiment model under the dosage of 10 mg / kg-20 mg / kg. As an anti-depression drug, compared with an existing 5-HT2A agonist, the compound has a relatively strong anti-depression effect, but the carboline compound does not have a magical effect and has a prospect of being developed into an anti-depression treatment drug.

The invention relates to the field of biological medicine, in particular to vortioxetine and application of pharmaceutically acceptable salts, solvates, crystal forms and prodrugs of vortioxetine to preparation of drugs for preventing or treating pathogenic fungal infection. The application reveals that the antidepressant vortioxetine (vortioxetine) and hydrobromide thereof (vortioxetine. HBr) which are sold on the market have measurable in-vitro inhibitory activity on various clinical common pathogenic fungi for the first time, so that the pharmacological action spectrum of the compound is expanded, and a new candidate direction is provided for research and development of antifungal drugs; the application not only overcomes the defects of existing antifungal drugs in the aspects of drug resistance, biological membranes and safety, but also opens up a brand new application direction of mental small molecule drugs in the anti-infection field, and has remarkable technical innovation, social value and industrial popularization prospect. The application also provides a theoretical basis for establishing a'multi-modal micromolecular antifungal library ', and can promote the development of pharmacological mechanism research and fungal infection precise treatment.

The present invention relates to a combination, a combination for treating a psychiatric disorder in a patient, a method for treating a psychiatric disorder in a patient, a kit, a dosing regimen, a delivery device, a method of adjuvant therapy, a short-acting magical agent for treating a psychiatric disorder in a patient or a parenteral formulation for treating a psychiatric disorder in a patient. In particular, the present invention relates to the combined administration of a short acting magical agent with a monoamine antidepressant, such as a selective serotonin reuptake inhibitor (SSRI).

The invention discloses a compound with remarkable 5-hydroxytryptamine (5-HT) reuptake inhibition activity, a preparation method of the compound and application of the compound in preparation of anti-depression drugs. And the compound is a compound Oreonudine C. The invention further discloses a preparation method of the compound. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, and performing silica gel column chromatography, C18 ODS column chromatography and preparative high performance liquid chromatography on the chloroform extraction part to obtain the Oreonudine C. The invention further discloses a preparation method of the Oreonudine C. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, and obtaining the Oreonudine C. In-vitro experiments show that the compound Oreonudine C remarkably inhibits reabsorption of 5-HT (the inhibition rate is 60.4%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine C is superior to that of a positive control drug amitriptyline (the inhibition rate is 53.6%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The application belongs to the technical field of biomedicine, and particularly relates to a benzene sulfonamide derivative and application thereof in antidepressant drugs. The structural general formula of the compound is (I). The compound or a pharmaceutically acceptable salt thereof has agonistic activity on 5-hydroxytryptamine 2A type receptors. The compound is determined to have good antidepressant activity through a mouse tail suspension test model, an open field test model and a forced swimming test model, is a novel antidepressant compound with wide application prospect, has no hallucinogenic effect, and can be developed into an antidepressant therapeutic drug.

The invention provides an application of lilium lancifolium exosome in preparation of a medicine for treating depression. The lilium lancifolium exosome has a unique nano-structure, is better in biocompatibility, can accurately target pathological cells, penetrate a biological membrane and a blood brain barrier, reduces damage to normal cells, directly acts on a central nervous system, is less in dosage, is safer in clinical use, has many side effects when being used as an antidepressant drug, and is high in treatment resistance and recurrence risk, and the like. A brand-new efficient solution is provided, and existing treatment bottlenecks are expected to be broken through.

The invention relates to application of broad bean pyrimidine in preparation of antidepressant drugs, and belongs to the technical field of biological medicines. Depression is a common and high-disability heavy mental disorder, has the core characteristics of remarkable and lasting emotion lowering and interest loss, seriously damages the social functions and life quality of patients, and has become one of the major public health burdens in the world. Based on new cognition of complex mechanisms of diseases, a new generation of antidepressant drugs which have a brand new action mechanism, can more accurately intervene in core pathological links of the diseases and can better meet the clinical requirements are researched and developed, and the new generation of antidepressant drugs are not only an inevitable direction for promoting psychopharmacology progress, but also are urgent medical necessities for improving prognosis of hundreds of millions of patients and relieving social burdens. A per2- / -mutant zebrafish depression model is used for performing drug screening on traditional Chinese medicine monomers, and finally it is found that 10 mM of broad bean pyrimidine has the anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish.

The present invention relates to combinations, combinations for use, methods of treatment, kits, dosing regimens, delivery devices, adjunctive treatment methods, short-acting psychedelic agents for use, or parenteral formulations for use, for treating mental disorders in patients. In particular, the present invention relates to administering short-acting psychedelic agents in combination with monoamine antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a preparation method of compound radix bupleuri depression-relieving dropping pills and application of the compound radix bupleuri depression-relieving dropping pills in antidepressant drugs. According to the dropping pill preparation, medicine simplification and optimization are carried out on the basis of Xiaoyao powder, meanwhile, the dissolution rate of insoluble components is improved by adopting a solid dispersion technology, the formability and the medicine loading capacity of the dropping pill are optimized by using a compound matrix and a nano flow aid, and the slow-release coating technology meets the slow-release requirement of circadian rhythmic depression. Meanwhile, the dissolution rate and the stability of effective components are improved, and the sustained release characteristic is achieved, so that the composition is suitable for preventing and treating depression.

The invention belongs to the technical field of medicines, and particularly relates to an esketamine and mirtazapine synergistic antidepressant pharmaceutical composition and application thereof. The antidepressant pharmaceutical composition comprises the following active components: esketamine and mirtazapine, the esketamine is an N-methyl-D-aspartic acid receptor antagonist, and the mirtazapine is an adrenergic alpha2-AR antagonist. According to the anti-depression pharmaceutical composition containing esketamine and mirtazapine, through the synergistic effect of esketamine and mirtazapine, the effects of reducing dosage, prolonging aging and reducing adverse reactions are achieved, and major depressive disorder is safely and effectively prevented and treated.

This invention provides a method for predicting antidepressant drugs. Based on a combination of knowledge graph, transcriptomics, and machine learning technologies, it screens potential drugs for depression. Specifically, it integrates disease-related node files, relation files, and transcriptomic data to construct information in triplet form, which is then imported into a model and converted into digital tensor information for scoring. The training dataset includes antidepressant tags from ClinicTrials and DrugBank, as well as other non-antidepressant drugs, combined with differential gene expression data obtained using RNA-seq technology. Multiple scoring models, such as TransE, TransR, DistMult, and ComplEx, are used for training and evaluation to screen potential antidepressant drugs. This method has the advantages of low cost, high efficiency, and wide applicability, significantly improving the accuracy and efficiency of antidepressant drug screening, providing a new drug discovery pathway for the treatment of depression, and helping to accelerate the research and development process of antidepressant drugs.

The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.

The application belongs to the technical field of medicine, and discloses a combined medicine for treating depression and application thereof. The combined medicine provided by the application comprises an antidepressant and artemisia indica simultaneously administered and / or sequentially administered. The application realizes the antidepressant effect of the combined use of the antidepressant and artemisia indica, effectively prevents and reduces liver injury caused by the antidepressant, expands the user group of the antidepressant, and has important significance in the clinical treatment of depression.

The invention discloses a novel active peptide composition for regulating emotion and application thereof. Belongs to the technical field of active peptides. In the process of extracting new active peptides from brain peptide by taking brain peptide as a raw material, various new active peptides, including VVAVP and VVAVPGN, are found, the efficacy of the new active peptides is further studied, and experimental results show that VVAVP and VVAVPGN have a certain anti-depression effect, but when VVAVP and VVAVPGN synergistically act on mice at the same time according to a ratio of 1: 1-1: 3, the anti-depression effect of VVAVP and VVAVPGN is remarkably improved, and the anti-depression effect of VVAVP and VVAVPGN is remarkably improved. It is accidentally found that the anti-depression effect is multiplied, it is indicated that when fluoxetine and fluoxetine are mixed in a specific proportion, the synergistic effect is achieved in the anti-depression aspect, the anti-depression effect can be remarkably improved, the effect is equivalent to that of fluoxetine in a positive control group, and a new research direction is provided for research and development of anti-depression drugs.

The invention belongs to the technical field of medicines, and particularly relates to an antidepressant pharmaceutical composition and application thereof. The antidepressant pharmaceutical composition is prepared from the following active ingredients: esketamine and mianserin, the esketamine is an N-methyl-D-aspartic acid receptor antagonist, and the mianserin is a central presynaptic adrenergic alpha2-AR antagonist. The invention further discloses a preparation method of the pharmaceutical composition. Escketamine and mianserin play an anti-depression role in different ways, and after combined use, not only is the drug dosage of the escketamine reduced, but also the anti-depression action time of the escketamine is prolonged, and a synergistic amplification effect is generated.

The invention belongs to the technical field of chemical analysis and detection, and particularly relates to a magnetic eutectic solvent, a preparation method and application thereof, and a pretreatment method and a quantitative detection method of wastewater containing antidepressant drugs. The magnetic eutectic solvent provided by the invention comprises a hydrogen bond acceptor, a hydrogen bond donor and cobalt chloride, the hydrogen bond acceptor comprises tri-n-octylphosphine oxide; the hydrogen bond donor comprises aniline, acetamide, ethylene glycol, 1, 3-propylene glycol, thymol or L-menthol; the molar ratio of the hydrogen bond acceptor to the hydrogen bond donor is (1-4): (1-3); the molar ratio of the hydrogen bond acceptor to the cobalt chloride is (1-4): 0.5. The magnetic eutectic solvent provided by the invention has the characteristics of simple preparation and environmental friendliness; the extraction process is simple and convenient and separation is easy to realize when the compound is used as an extraction agent to extract the antidepressant in wastewater, the wastewater pretreatment process is remarkably simplified, and an efficient pretreatment method is provided for accurate detection of trace drug residues in a complex matrix.

The invention relates to the technical field of medicines, in particular to application of artemisia vulgaris in preparation of an anti-depression medicine. According to the application disclosed by the invention, the depression is systematically researched through a chronic depression model induced by chronic unpredictable mild stress (CUMS) and an acute depression model induced by lipopolysaccharide (LPS). Experimental results show that under the stimulation of CUMS or LPS, experimental animals show obvious depression-like behaviors. Compared with a negative control group, depression-like behaviors of mice in the CUMS model group and the LPS model group are confirmed, and behavior abnormalities induced by the two models can be effectively improved after intervention of the artemisinin. Further comparative research finds that the antidepressant effect of the clinically common antidepressant drug venlafaxine with the dosage of 10 mg / kg can be achieved under the dosage of 1 mg / kg of the artemisinin, and the artemisinin has remarkable antidepressant activity. The application has a good application prospect when being applied to the development of anti-depression drugs.

The invention relates to the technical field of gene determination, in particular to an SNP (Single Nucleotide Polymorphism) site detection kit for predicting medication for treating depression, which comprises a data acquisition module, a gene restriction analysis module, a drug recommendation analysis module and a drug recommendation generation module. The gene interpretation data at least comprises a gene interpretation table and a gene drug corresponding table; on the basis of a gene interpretation table, analyzing common metabolism influence of different detection sites on metabolism of the same antidepressant drug, and determining gene comprehensive limitation degrees of different antidepressant drugs and disease-resistant drugs; and based on the gene drug corresponding table, analyzing the burden degree of the disease-resistant drug combination on the metabolic capability of the patient, and determining the recommendation prediction degree of different disease-resistant drugs in combination with the comprehensive limitation degree of the gene, thereby generating a drug recommendation table of the current patient. According to the method, the recommendation prediction degrees of different disease-resistant drugs are accurately determined, so that the accuracy of the generated drug recommendation report is improved.

The invention provides a pyrrolidone tricyclic compound and a preparation method thereof, and application of the pyrrolidone tricyclic compound in preparation of drugs for treating neurodegenerative diseases, especially antidepressant drugs. The structural formula of the pyrrolidone tricyclic compound is as shown in general formulas A and 13. Experimental studies on in-vitro PC12 cell injury protection activity, in-vivo mouse anti-depression activity, hERG potassium channel inhibition and mouse head shaking show that the compound disclosed by the invention can be used for preparing neurodegenerative diseases, especially quickly-acting anti-depression drugs, and has the remarkable advantage of improving the spermatogenesis function.

The present invention discloses a tea polyphenol-derived carbon dot, a preparation method thereof, and its application in the preparation of an antidepressant, comprising the following steps: tea polyphenol and fluoxetine hydrochloride are used as reaction raw materials, subjected to microwave heating reaction, dissolved in water after the reaction is complete, then filtered, dialyzed, and freeze-dried to obtain the tea polyphenol-derived carbon dot. The raw material used in the present invention is the natural product tea polyphenol. The prepared carbon dots have good fluorescence properties, rich surface groups, low toxicity, and are easily cleared by the kidneys. Cell models and zebrafish animal models have shown that the M-CDs prepared by the present invention have good biosafety and can significantly improve the depressive-like behavior of zebrafish, restoring the zebrafish's cortisol and monoamine neurotransmitters to normal levels. The M-CDs prepared by the present invention have good water solubility and are expected to be used as a new antidepressant for further application research.

The application belongs to the technical field of biological medicine, and specifically discloses application of seco-oxymatrine in preparation of an antidepressant, wherein the antidepressant further contains a pharmaceutically acceptable carrier; the antidepressant is one of an oral preparation, an inhalant and an injection; the oral preparation is one of a suspension, an emulsion, a solution, a powder, a tablet, a granule and a capsule. When seco-oxymatrine is used as an effective component of the antidepressant, the depressive behavior of a LPS-induced depressive model mouse can be effectively improved.

The application discloses a tail suspension test device and method for evaluating the behavioral despair of mice after stroke, wherein a slope plate is arranged below the hanging piece for hanging the mice in the hanging chamber, so as to prevent the mice from struggling due to movement coordination disorders, to help the suspended mice keep balance, and to prevent the mice from shaking even if the movement ability of the mice is impaired, and the application is particularly suitable for evaluating the despair of the mice with impaired movement coordination after stroke. The application supports part of the body weight of the mice through the slope plate, the pain caused during the test is slight, and the application can also be used for rats once the size of the device is adapted to the rats. The application is a modified detection method (mTST for short) of TST, and is used for evaluating the behavioral despair of the mice after stroke. The application can be applied to the evaluation of the curative effect of antidepressant drugs on the model mice of chronic mild stress (CMS) and post-stroke depression (PSD), and is favorable to the basic research of diseases such as PSD and the clinical transformation of drugs.

The invention belongs to the technical field of biological medicine, and particularly discloses application of secoxyloganin in preparation of an antidepressant drug, and the antidepressant drug further contains a pharmaceutically acceptable carrier. The antidepressant drug is one of an oral preparation, an inhalant and an injection; the oral preparation is one of a suspending agent, an emulsion, a solution, powder, tablets, granules and capsules. When the secoxyloganin is used as the effective component of the antidepressant drug, the depression-like behavior of a depression model mouse induced by LPS (Lipopolysaccharide) can be effectively improved.

The invention belongs to the technical field of biological medicine, and provides application of a flavonoid compound in preparation of an antidepressant drug and the antidepressant drug. In-vitro enzyme activity experiments find that the flavonoid compound has a remarkable inhibiting effect on DBH and MAO enzyme activity and has a remarkable promoting effect on DDC enzyme activity for the first time. In a chronic social contusion stress (CSDS) mouse model, the flavonoid compound (1mg / kg) is continuously injected into the abdominal cavity for 7 days, the social avoidance behavior and the behavioral despair behavior of the model mouse can be remarkably improved through behavioral tests such as a social interaction experiment (SIT), a sucrose preference experiment (SPT), a forced swimming experiment (FST) and a tail suspension experiment (TST), and a rapid anti-depression effect is shown. The in-vitro and in-vivo researches clearly prompt that the flavonoid compound has the effect of quickly and remarkably treating depression.

Compositions and methods for treating neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss-related, and / or metabolic diseases including Spinal Muscular Atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also known as Types I, II, III, and IV), Traumatic Brain Injury (TBI), concussion, keratoconjunctivitis sicca (dry eye disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK, antidepressant use, Wolfram syndrome, and Wolcott-Rallison syndrome. The compositions are selected from 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bis 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; bisprodrug, bioprecursor molecules, and combinations thereof.

The invention discloses new application of cynanchum otophyllum saponin T, namely application of the cynanchum otophyllum saponin T in preparation of depression treatment medicines, experimental results show that the cynanchum otophyllum saponin T has the effect of improving cognitive impairment in mice with LPS (lipopolysaccharide)-induced depression, and proves that the cynanchum otophyllum saponin T has the effect of treating depression; the comparison between the structure of the cynanchum otophyllum saponin T and the structure of antidepressant drugs approved by FDA on the market shows that the structure of the cynanchum otophyllum saponin T is a new compound for treating depression, and a prostaglandin receptor EP4 is used as an antidepressant target.

The invention relates to the field of biological medicine, and aims to provide an application of a ginseng preparation in preparation of an antidepressant drug, the antidepressant drug is a ginseng preparation or an American ginseng preparation, the combination of ginsenosides Rh1, Rh2, Rg2, Rg3 and F2 in the preparation accounts for more than 25% of the total saponins in the preparation, the dosage of the antidepressant drug is 1.0-2.5 mg / kg per day according to the combined weight of Rh1, Rh2, Rg2, Rg3 and F2, and the dosage of the antidepressant drug is 1.0-2.5 mg / kg per day according to the combined weight of Rh1, Rh2, Rg2, Rg3 and F2. Other traditional Chinese medicines, traditional Chinese medicine extracts and pharmaceutically acceptable auxiliary materials can be added into the preparation, and the administration mode of the antidepressant medicine is oral administration. The ginseng preparation has the beneficial effect that the effect of treating depression is remarkable.

The invention discloses an application of polypeptide in preparation of antidepressant drugs, and belongs to the field of biological medicine, the polypeptide is neuropeptide PEN or a functional fragment and a derivative thereof, and the PEN is one of a plurality of derivative peptides formed by cutting a protein precursor proSAAS existing in a central nervous system of a mammal through proprotein convertase. Research finds that PEN as an endogenous polypeptide can significantly shorten the immobility time of a mouse in a tail suspension experiment and a forced swimming experiment and improve the depression-like behavior of the mouse, shows an obvious anti-depression effect, and has no obvious influence on the movement function of the mouse. A further research result shows that the anti-depression mechanism of PEN is related to inhibition of NMDAR2B / CaMKII signals of a mouse hippocampus and increase of ERK1 / 2 protein activity of the hippocampus. The invention discovers potential application of PEN in preparation of antidepressant drugs for the first time, and provides a new target and theoretical basis for development of novel, safe and effective antidepressant drugs.

The invention belongs to the technical field of medicines, and particularly discloses a novel chalcone compound as well as a preparation method, a pharmaceutical composition and application thereof. The chalcone compounds (+)-lupulusone D and (-)-lupulusone D provided by the invention have not been reported at present. Experimental results show that the chalcone compounds (+)-lupulusone D and (-)-lupulusone D provided by the invention have a remarkable protection effect on corticosterone-induced SH-SY5Y cells, are obviously superior to a positive drug fluoxetine, and can be used for developing drugs for treating depression.